Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity
Expert Review of Anticancer Therapy, 2021 A decrease in relative-dose intensity (RDI) of chemotherapy has been shown to be associated with poor patient outcomes in solid tumors and non-Hodgkin's lymphoma. The actual delivered chemotherapy dose received by patients can be influenced by dose reductions and treatment delays, often due to toxicities, most commonly chemotherapy-induced neutropenia (
Gary H Lyman
exaly +3 more sources
Integrative Cancer Therapies, 2023 Background: When it comes to chemotherapy, maintaining the dose and schedule of treatment are of vital importance, as clinical evidence suggests that dose intensity is associated with optimal treatment outcomes for various tumors.
Karen Y. Wonders PhD, FACSM +2 more
doaj +3 more sources
Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience
Current Oncology, 2009 Adjuvant chemotherapy for early breast cancer improves disease-free and overall survival in pre- and postmenopausal women. The importance of maintaining relative dose intensity (rdi) is well-known; however, little information is available from routine clinical practice regarding how well dose intensity is maintained with modern chemotherapy regimens ...
Raza, S., Welch, S., Younus, J.
exaly +3 more sources
Relative dose intensity of systemic chemotherapy in an outpatient cancer center
Acta Medica Academica, 2010 Objective. This study was undertaken to determine the average relative dose intensity (RDI) of chemotherapy administered to patients in a community-based outpatient cancer center. Methods.
Christine Uptigrove +3 more
doaj +1 more source
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices [PDF]
Journal of the National Comprehensive Cancer Network: JNCCN, 2015 A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile neutropenia, are among the most common side effects of chemotherapy, and they often necessitate delays or reductions in doses of myelosuppressive agents. Reduced relative dose intensity (RDI) may
Gary H Lyman
exaly +3 more sources
Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer [PDF]
Contemporary Oncology, 2020 Ilfad Blazevic +3 more
doaj +2 more sources
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients [PDF]
Cancer Medicine, 2019 The prognosis of diffuse large B‐cell lymphoma (DLBCL) patients depends on lymphoma‐ and patient‐related risk factors and is best estimated by the international prognostic index (IPI).
Monika Długosz‐Danecka +4 more
doaj +2 more sources
Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma. [PDF]
Cancers (Basel)Background: Daratumumab (DARA), lenalidomide (LEN), and dexamethasone (DEX, DRd) are one of standards of care for patients with multiple myeloma (MM); however, the clinical impact of relative dose intensity (RDI) remains unclear. In this retrospective study, the aim was to analyze the relationship between the RDI and clinical outcomes in patients with ...
Suzuki K +7 more
europepmc +3 more sources
Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer. [PDF]
Cancer Epidemiol Biomarkers Prev, 2023 Abstract Background: Despite evidence that low muscle increases the risk of chemotoxicity, most chemotherapies are dosed on body surface area without considering body composition. Among 178 patients with colon cancer, we assessed muscle and adipose tissue with multiple techniques and examined ...
Cheng E +12 more
europepmc +3 more sources
Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment [PDF]
PeerJ, 2023 Objectives To determine the relationship between chemotherapy dose delay/reduction with progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients treated with FOLFIRI based first-line chemotherapy in real-world ...
Xia Zhang +7 more
doaj +2 more sources